ArticleCNS neuroscience & therapeutics2026
Pharmacokinetics and Neuroprotective Efficacy of Poly-Arginine Peptide R18D in Sprague Dawley Rats Subjected to Transient Intraluminal Filament Middle Cerebral Artery Occlusion Stroke.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis study examined the dose-dependent efficacy and pharmacokinetics of R18D in a rat transient middle cerebral artery occlusion (MCAO) stroke model.
methodsR18D was intravenously administered 60 min after the onset of a 90-min MCAO induced by intraluminal filament insertion. For pharmacokinetic profiling, blood samples were collected 10, 15, 30 and 60 min, and at 2, 4 and 8 h after the start of a 10-min intravenous infusion of R18D. Infarct volume and body weight were assessed at 24 h after MCAO.
resultsR18D reduced mean total infarct volume by 47.2% (p = 0.0003), 28.4% (p = 0.008), and 27.9% (p = 0.003) at doses of 325, 650 and 1100 nmol/kg, respectively. The 650 nmol/kg dose significantly reduced cerebral hemisphere swelling by 8.3% (p = 0.01), whereas the 325 nmol/kg (5.6%; p = 0.15) and 1100 nmol/kg (4.5%; p = 0.14) doses produced non-significant reductions in swelling. R18D did not significantly affect post-stroke weight loss, however rats treated with the lowest dose (325 nmol/kg) exhibited the smallest reduction in body weight compared with vehicle-treated animals (7.35% vs. 9.35). Pharmacokinetic analysis of the three R18D doses after stroke demonstrated a half-life of 72 to 78 min, with dose-dependent plasma Cmax values of 5.3 μg/mL, 11.9 μg/mL and 17.3 μg/mL for the low-, medium- and high-dose groups, respectively.
conclusionsThese results further support the neuroprotective properties of R18D and provide strong justification for its continued development as a neuroprotective treatment for ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.